US Patent

US9693979 — Liquid dosage forms of sodium naproxen

Formulation · Assigned to Banner Life Sciences LLC · Expires 2026-03-03 · 0y expired

Vulnerability score 28/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects liquid dosage forms of sodium naproxen in soft gel capsules.

USPTO Abstract

Described herein are oral pharmaceutical compositions comprising liquid dosage forms of sodium naproxen in soft gel capsules. In one embodiment, the pharmaceutical composition comprises sodium naproxen, 0.2-1.0 mole equivalents of a de-ionizing agent per mole of naproxen, polyethylene glycol, and one or more solubilizers such as propylene glycol, polyvinyl pyrrolidone or a combination thereof.

Drugs covered by this patent

naproxen-sodium (NAPROXEN SODIUM)

Patent Metadata

Patent number: US9693979
Jurisdiction: US
Classification: Formulation
Expires: 2026-03-03
Drug substance claim: No
Drug product claim: Yes
Assignee: Banner Life Sciences LLC
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.